WASHINGTON (AP) — The Food and Drug Administration (FDA) has taken groundbreaking steps by announcing ultra-fast review processes for three psychedelic drugs aimed at tackling mental health conditions such as severe depression. This latest development underscores the current administration's advocacy for experimental treatment approaches in psychiatry.
Recently, President Donald Trump signed an executive order mandating the FDA to relax restrictions on psychedelics, a class of hallucinogenic substances that remain illegal federally. This order seeks to advance the availability of alternatives to traditional mental health therapies.
The FDA granted priority review vouchers to two companies researching psilocybin, a compound derived from magic mushrooms used for treatment-resistant depression. Another company received funding for methylone, a substance associated with post-traumatic stress disorder (PTSD). While the FDA did not disclose the names of these companies, the issuance of priority vouchers could significantly shorten review timelines from months to weeks, although it does not guarantee approval.
These developments resonate with an expanding public support for psychedelics, particularly among supporters of Trump's administration, which notably includes combat veterans advocating for these treatments. This momentum aligns with the 'Make America Healthy Again' initiative led by Health Secretary Robert F. Kennedy Jr., which has positioned psychedelics at the forefront of health discussions within the political landscape.
Last year, Kennedy expressed his department's goal to have psychedelics accessible for difficult-to-treat psychiatric conditions within a year. As a former Kennedy campaign aide, Calley Means has become a vocal advocate for the potential of psychedelics in therapeutic contexts, reinforcing their perceived 'mind-blowing' potential.
This FDA initiative will draw attention to its rapid drug review operations, particularly the Commissioner’s National Priority Voucher program, which has been scrutinized for favoring politically aligned companies.
In a related initiative, the FDA sanctioned early-stage testing of a drug linked to ibogaine, a potent psychedelic that has garnered attention for its potential benefits for those battling alcohol dependency. DemeRx, the company overseeing this drug's development, contends that its formulation minimizes the dangers associated with traditional ibogaine usage.
Saturday's White House event spotlighted investments in psychedelic research, suggesting that Trump's administration is keen on prioritizing these alternative therapies following endorsements from influential figures such as Joe Rogan, enhancing their visibility within contemporary discourse surrounding mental health treatments.
